First authorYear | Instrument and year of development | Domains/scales of QoL | Items | Uveitis relevant items, n | Country | Patients, N | Patient characteristics | Completion time |
---|---|---|---|---|---|---|---|---|
Uveitis | Â | |||||||
Barry 2014 [25] | 3 PROMS: BD&MSQ Qol BCR Qol Meds | BD&MSQ 8 (lights, vision, skin, body pain, breathless, mood, sleep, hair loss) QoL BCR 4 (mood/ relationship, daily activities, family relations, feeling unwell) QoL Meds 3 (mood/ relationships, vision, low mood) | BD&MSQ 21 QoL BCR: 20 QoL Meds: 12 | BD&MSQ:7 QoL BCR:3 QoL Meds: 4 | UK, national patient group | 2 patients for initial content; 8 for instrument development; 150 for validation plus 33 healthy controls | Birdshot chorioretinopathy patients (n = 152) Mean age 53.1 (SD 9.6) years, 73.0% female | Not reported |
Wu 1996 [26] | CMV Retinitis (no formal instrument name), 1992 | Visual symptoms (5 items); visual function (7 items); global vision (2 items), impact of treatment (4 items) | 18 | 14 | USA, 7 sites | 18 to develop item content; 26 to develop and validate instrument | CMV retinitis patients with AIDS (n = 26). Mean age 38.5 (SD 5.9) years, 96% male, 88% White | 5 min |
Martin 2001 [27] | CMV Retinitis (no formal instrument name, Wu 1996) VALIDATION STUDY | This study included 4 scales with 16 items from Wu et al. 1996: Visual symptoms (5 items), visual function (7 items), global vision (2 items); impact of treatment (2 items) | 16 | 14 | USA, 12 sites, 1992–1995 | 279 patients recruited in the CRRT trial | CMV retinitis patients (n = 279). Mean age 38.6 years, 91.8% male, 60.6% White | Not reported |
Mangione 2001 [29] | NEI VFQ-25 | 9 subscales: General health (1 item), general vision (1 item), near vision (3 items), distance vision (3 items), ocular pain (2 items), colour vision (1 item), peripheral vision (1 item), driving (3 items); and VISION-SPECIFIC social functioning (2 items), mental health (4 items), dependency (3 items), and role limitations (2 items) | 26 | 25 | USA | Data from n = 262 pilot study and n = 597 field test who completed an earlier 51-item instrument, for validation | N = 262 of which n = 21 CMV retinitis. Mean age 61 years, 54% female, 81% White N = 597 of which n = 37 CMV retinitis. Mean age 64 years, 59% female, 63% White | Aimed to be 5 min, but not reported |
Normative comparison [32] | NEI-VFQ-25 for uveitis VALIDATION STUDY | General health 1 plus 25-items as above (Mangione 2001) | 26 | 25 | 18 countries, 46 sites | N = 224 HURON RCT patients compared to NEI VFQ data from n = 122 [29] | Patients (n = 224) including 188 with intermediate, and 44 with posterior uveitis. Mean age 44.6 (SD 14.3) years, 63.4% female, 60.3% White | Not reported |
Patel [28] | KSQ | 5 modules: general health status, lung, skin, eye and medication | 29 | 7 in eye module, with 10 General Health Status forming unidimensional set | UK | Content: 23 (including 7 with ocular sarcoidosis) Development and validation: 207 patients | 100% sarcoidosis, n = 45/207 with ocular involvement | Mean 10 (SD 8) minutes |
Scleritis | Â | |||||||
No studies | Â | Â | Â | Â | Â | Â | Â | Â |